Role of PI3K Inhibitors in R/R Follicular Lymphoma

Opinion
Video

Faculty highlight recent changes in treatment guidelines surrounding the use of PI3K inhibitors in follicular lymphoma and discuss the evolving role of these agents in the treatment landscape.

Recent Videos
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Related Content
Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

Chris Ryan
September 10th 2024
Article

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

The European Commission’s decision represents the first regulatory approval of odronextamab for patients with follicular lymphoma or DLBCL.

Odronextamab Earns European Approval in R/R Follicular Lymphoma, DLBCL

Russ Conroy
August 26th 2024
Article

The European Commission’s decision represents the first regulatory approval of odronextamab for patients with follicular lymphoma or DLBCL.

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Epcoritamab Approval Expands Bispecific Use in Follicular Lymphoma

Tycel Phillips, MD
July 8th 2024
Podcast

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

FDA Approval Alert: Epcoritamab in Relapsed/Refractory Follicular Lymphoma

FDA Approval Alert: Epcoritamab in Relapsed/Refractory Follicular Lymphoma

ONCOLOGY Staff
August 22nd 2024
Article

The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.

Conditional marketing authorization for epcoritamab in the European Union is based on findings from the phase 1/2 EPCORE NHL-1 trial.

Epcoritamab Earns EU Approval in Relapsed/Refractory Follicular Lymphoma

Russ Conroy
August 20th 2024
Article

Conditional marketing authorization for epcoritamab in the European Union is based on findings from the phase 1/2 EPCORE NHL-1 trial.